Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Neurology

Standard of Care: Treatments and Management Strategies

At a Glance

While there is no universal cure for Autosomal Recessive Cerebellar Ataxia (ARCA), targeted therapies like Skyclarys for Friedreich’s Ataxia and Vitamin E for AVED can slow disease progression. Management relies on a combination of medications and multidisciplinary rehabilitation.

While most forms of Autosomal Recessive Cerebellar Ataxia (ARCA) do not yet have a universal “cure,” modern management focuses on a dual approach: targeting the underlying biological cause where possible and maximizing your daily function through specialized care [1][2].

Targeted and Disease-Modifying Therapies

For a few specific subtypes, treatments now exist that can slow or even stop the progression of the disease.

  • Friedreich’s Ataxia (FRDA): Omaveloxolone (Skyclarys) is the first medication approved by the FDA and EMA for patients 16 and older [3][4]. In clinical trials, it improved neurological function and slowed disease progression [5][6]. Important Safety Note: Omaveloxolone can cause fluid retention, which may exacerbate heart failure—a significant risk since many FRDA patients have cardiomyopathy [7][8]. It requires strict clinical oversight, including regular monitoring of heart function (BNP levels), liver enzymes, and lipids.
  • Ataxia with Vitamin E Deficiency (AVED): This is a uniquely “treatable” ataxia. Because the body cannot properly use Vitamin E, the nerves begin to degenerate. High-dose Vitamin E supplementation can halt the disease and, if started early enough, may even reverse some symptoms [1][9].

Symptomatic Medications

Beyond disease-modifying drugs, doctors can prescribe medications to manage the daily symptoms of ataxia itself. While these do not stop the disease, they can improve quality of life. For example, drugs like 4-aminopyridine are sometimes used to treat nystagmus (involuntary eye movements) or minor balance issues, and specific anti-spasmodics can be prescribed to relieve painful muscle tightness and spasticity [10][11].

Multidisciplinary Rehabilitation: The “Cornerstone” of Care

Regardless of your specific subtype, a multidisciplinary rehab team is essential. This is specialized therapy designed specifically for the ataxic brain [2][12].

  • Physical Therapy (PT): Focuses on “postural training” to help the brain compensate for balance loss and prevent falls [13][2].
  • Occupational Therapy (OT): Helps you adapt your environment and learn new ways to perform daily tasks to conserve energy and maintain fine motor skills [12].
  • Speech Therapy (ST): Assists with dysarthria (slurred speech) and dysphagia (swallowing difficulties), which can occur in many ARCA subtypes [2].

Managing “Extra” Complications

ARCA can sometimes affect parts of the body other than the brain. Managing these “non-neurological” symptoms is a vital part of the standard of care.

Subtype Potential Complication Management Approach
FRDA Cardiomyopathy Regular monitoring with EKGs and echocardiograms. Medications like ACE inhibitors may be used to support heart function [14][15].
FRDA Diabetes Up to 10% of FRDA patients develop diabetes. Routine monitoring of HbA1c and referral to an Endocrinologist [16].
A-T Immunodeficiency Monitoring immune levels (IgA/IgG) and proactive screening for certain cancers [17][18].
ARSACS Spasticity Using medications or physical therapy to manage severe muscle tightness [19][11].

Next Step: Find out exactly who you need on your care team in Building Your Care Team and Preparing for Appointments.

Common questions in this guide

What is the best treatment for Autosomal Recessive Cerebellar Ataxia?
Treatment depends entirely on your specific ARCA subtype. While there is no universal cure, options include targeted therapies like Skyclarys for Friedreich’s Ataxia, high-dose Vitamin E for AVED, and specialized physical rehabilitation for all patients.
Can physical therapy help with ataxia symptoms?
Yes, physical therapy is a cornerstone of ataxia care. Specialized physical therapists use postural training to help your brain compensate for balance loss, improve daily mobility, and prevent dangerous falls.
Are there medications to manage daily ataxia symptoms?
Doctors can prescribe specific medications to improve your daily quality of life and manage discomfort. For example, 4-aminopyridine may help with involuntary eye movements, and anti-spasmodics can relieve painful muscle tightness.
What is Skyclarys (omaveloxolone) used for?
Skyclarys is the first FDA-approved medication for patients 16 and older with Friedreich’s Ataxia. It has been shown to improve neurological function and slow disease progression, though it requires careful clinical monitoring for side effects like fluid retention.
Why do I need to see other specialists if I have a neurological condition?
Because ARCA can affect parts of the body outside the brain, you may need specialists to manage extra complications. For instance, you might need a cardiologist to monitor for cardiomyopathy or an endocrinologist if you develop diabetes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a candidate for omaveloxolone (Skyclarys), and if so, how do we monitor its effectiveness and safety?
  2. 2.What is my current serum Vitamin E level, and are we certain my subtype isn't the one that responds to high-dose supplementation?
  3. 3.Are there any symptomatic medications, like 4-aminopyridine, that could help manage my current symptoms?
  4. 4.Can you refer me to a physical therapist who has specific expertise in cerebellar ataxia rather than general rehabilitation?
  5. 5.How often should we be re-evaluating my functional scores (like SARA or mFARS) to track my progression?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Ataxia due to vitamin E deficiency: A case report and updated review.

    Thapa S, Shah S, Chand S, et al.

    Clinical case reports 2022; (10(9)):e6303 doi:10.1002/ccr3.6303.

    PMID: 36093469
  2. 2

    Guidelines on the diagnosis and management of the progressive ataxias.

    de Silva R, Greenfield J, Cook A, et al.

    Orphanet journal of rare diseases 2019; (14(1)):51 doi:10.1186/s13023-019-1013-9.

    PMID: 30786918
  3. 3

    Omaveloxolone: First Approval.

    Lee A

    Drugs 2023; (83(8)):725-729 doi:10.1007/s40265-023-01874-9.

    PMID: 37155124
  4. 4

    Friedreich's ataxia-a rare multisystem disease.

    Reetz K, Lischewski SA, Dogan I, et al.

    The Lancet. Neurology 2025; (24(7)):614-624 doi:10.1016/S1474-4422(25)00175-9.

    PMID: 40541211
  5. 5

    Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension.

    Lynch DR, Chin MP, Boesch S, et al.

    Movement disorders : official journal of the Movement Disorder Society 2023; (38(2)):313-320 doi:10.1002/mds.29286.

    PMID: 36444905
  6. 6

    Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).

    Lynch DR, Chin MP, Delatycki MB, et al.

    Annals of neurology 2021; (89(2)):212-225 doi:10.1002/ana.25934.

    PMID: 33068037
  7. 7

    Early experience on omaveloxolone in adult patients with Friedreich's ataxia: a real-world observational study.

    Lima SM, Caltagirone M, Messina C, et al.

    Journal of neurology 2025; (272(11)):742 doi:10.1007/s00415-025-13487-1.

    PMID: 41176519
  8. 8

    Safety Monitoring of Omaveloxolone in Friedreich Ataxia: Results from One Year of Clinical Treatment.

    Gunther K, Profeta V, Keita M, et al.

    Neurology and therapy 2025; (14(3)):1105-1114 doi:10.1007/s40120-025-00749-3.

    PMID: 40304846
  9. 9

    Atypical retinopathy in ataxia with vitamin E deficiency: report of a sibship.

    Abramowicz S, Dentel A, Chouraqui M, et al.

    Neurogenetics 2024; (25(1)):33-38 doi:10.1007/s10048-023-00741-9.

    PMID: 38105315
  10. 10

    Differential Effects of Cerebellar Transcranial Direct Current Stimulation with Gait Training on Functional Mobility, Balance, and Ataxia Symptoms.

    Brito R, Fabrício JV, Araujo A, et al.

    Cerebellum (London, England) 2024; (23(6)):2457-2467 doi:10.1007/s12311-024-01750-6.

    PMID: 39367955
  11. 11

    Efficacy of Manual Wheelchair Skills Training for Improving Skills and Confidence in People With Hereditary Degenerative Disorders: Protocol for a Sequential Multimethods Study.

    Niyomwungere E, Routhier F, Gagnon C, et al.

    JMIR research protocols 2025; (14()):e66974 doi:10.2196/66974.

    PMID: 40742628
  12. 12

    Rehabilitation in patients with cerebellar ataxias.

    Chien HF, Zonta MB, Chen J, et al.

    Arquivos de neuro-psiquiatria 2022; (80(3)):306-315 doi:10.1590/0004-282X-ANP-2021-0065.

    PMID: 35239817
  13. 13

    Single-Session Cerebellar Transcranial Direct Current Stimulation Improves Postural Stability and Reduces Ataxia Symptoms in Spinocerebellar Ataxia.

    Brito R, Fabrício JV, Araujo A, et al.

    Cerebellum (London, England) 2024; (23(5)):1993-2002 doi:10.1007/s12311-024-01696-9.

    PMID: 38693314
  14. 14

    Heart disease in Friedreich's ataxia.

    Hanson E, Sheldon M, Pacheco B, et al.

    World journal of cardiology 2019; (11(1)):1-12 doi:10.4330/wjc.v11.i1.1.

    PMID: 30705738
  15. 15

    Diagnosis and Management of Cardiovascular Involvement in Friedreich Ataxia.

    Monda E, Lioncino M, Rubino M, et al.

    Heart failure clinics 2022; (18(1)):31-37 doi:10.1016/j.hfc.2021.07.001.

    PMID: 34776081
  16. 16

    Impact of diabetes in the Friedreich ataxia clinical outcome measures study.

    McCormick A, Farmer J, Perlman S, et al.

    Annals of clinical and translational neurology 2017; (4(9)):622-631 doi:10.1002/acn3.439.

    PMID: 28904984
  17. 17

    Cancer in Children With Fanconi Anemia and Ataxia-Telangiectasia-A Nationwide Register-Based Cohort Study in Germany.

    Dutzmann CM, Spix C, Popp I, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(1)):32-39 doi:10.1200/JCO.21.01495.

    PMID: 34597127
  18. 18

    Simple Measurement of IgA Predicts Immunity and Mortality in Ataxia-Telangiectasia.

    Zielen S, Duecker RP, Woelke S, et al.

    Journal of clinical immunology 2021; (41(8)):1878-1892 doi:10.1007/s10875-021-01090-8.

    PMID: 34477998
  19. 19

    MRI-ARSACS: An Imaging Index for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) Identification Based on the Multicenter PROSPAX Study.

    Scaravilli A, Negroni D, Senatore C, et al.

    Movement disorders : official journal of the Movement Disorder Society 2024; (39(8)):1343-1351 doi:10.1002/mds.29871.

    PMID: 38847051

This page provides information on standard treatments for Autosomal Recessive Cerebellar Ataxia for educational purposes only. Always consult your neurologist before starting or changing any medications or therapies.

Get notified when new evidence is published on Autosomal recessive cerebellar ataxia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.